Stay updated with breaking news from Cap Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zacks has put a US$2.03 price target on the stock, citing several upcoming catalysts such as a new PEA at Escalones and the acquisition of...
Company Connecting the Dots for Final FDA Approval New York, New York--(Newsfile Corp. - June 3, 2021) - PCG Digital -- When Soligenix (NASDAQ: SNGX) updated its NDA rollout plan, the market quickly reacted.
(3) New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key takeaways from the commercialization Q&A: 1. Soligenix will commercialize SGX301 in the U.S. on its own During the presentation, the company noted that after conducting ...